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Abstract
Background: Prognostic scores might be useful tools both in clinical practice and clinical trials,
where they can be used as stratification parameter. The available scores for patients with brain
metastases have never been tested specifically in patients with primary breast cancer. It is therefore
unknown which score is most appropriate for these patients.
Methods: Five previously published prognostic scores were evaluated in a group of 83 patients
with brain metastases from breast cancer. All patients had been treated with whole-brain
radiotherapy with or without radiosurgery or surgical resection. In addition, it was tested whether
the parameters that form the basis of these scores actually have a prognostic impact in this
biologically distinct group of brain metastases patients.
Results: The scores that performed best were the recursive partitioning analysis (RPA) classes and
the score index for radiosurgery (SIR). However, disagreement between the parameters that form
the basis of these scores and those that determine survival in the present group of patients and
many reported data from the literature on brain metastases from breast cancer was found. With
the four statistically significant prognostic factors identified here, a 3-tiered score can be created
that performs slightly better than RPA and SIR. In addition, a 4-tiered score is also possible, which
performs better than the three previous 4-tiered scores, incl. graded prognostic assessment (GPA)
score and basic score for brain metastases (BSBM).
Conclusion: A variety of prognostic models describe the survival of patients with brain metastases
from breast cancer to a more or less satisfactory degree. However, the standard brain metastases
scores might not fully appreciate the unique biology and time course of this disease, e.g., compared
to lung cancer. It appears possible that inclusion of emerging prognostic factors will improve the
results and allow for development and validation of a consensus score for broad clinical application.
The model that is based on the authors own patient group, which is not large enough to fully
evaluate a large number of potential prognostic factors, is meant to illustrate this point rather than
to provide the definitive score.
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Background
Over the last years, increasing efforts were made to better
understand prognostic factors in patients with brain metas-
tases from breast cancer. In principle, the results of such anal-
yses can be used to create prognostic scores, which might
support decision making and treatment recommendations.
The best known scores, such as the recursive partitioning
analysis (RPA) classes [1], the score index for radiosurgery
(SIR) [2] and the basic score for brain metastases (BSBM) [3],
were created from databases containing patients with brain
metastases from many different types of primary tumors.
Thus, only a minority of these patients actually had primary
breast cancer. The same holds true for two new scores pub-
lished in 2008 [4,5]. While SIR and BSBM were derived from
radiosurgery-treated patients, several studies showed that
they also predict survival in patients treated with other
approaches. As compared to the large group of patients with
brain metastases from lung cancer, the unique biological fea-
tures of breast cancer allow for therapeutic approaches that
might improve the response of both extra- and intracranial
disease manifestations (Trastuzumab, Lapatinib, aromatase
inhibitors etc.) [6,7]. Emerging data suggest that the increas-
ing use of these drugs might also impact on survival. In order
to avoid overuse of costly treatments and the potential side
effects of therapy, accurate prognostic models need to be
developed. These considerations led the authors to study the
usefulness of the 5 previously published prognostic scores in
this particular patient population. This first head to head
comparison of different survival prediction models and
review of literature results on emerging prognostic factors
confirmed that traditional prognostic factors such as per-
formance status and extracranial metastases are very impor-
tant, but it also suggests that better prognostic models than
RPA and SIR, which performed best in the present group of
patients, can be developed.
Methods
The authors used a previously described database of female
patients with brain metastases from breast cancer treated
with whole-brain radiotherapy (WBRT, most often 10 frac-
tions of 3 Gy administered via lateral opposing 6 MV pho-
ton beams that did not cover the upper cervical spine/optic
nerves) with or without surgery or radiosurgery [8] for com-
parison of 5 prognostic scores. The patients were treated at
the authors' institutions in Norway and Germany during
the last 10 years. For inclusion in this study it was required
that all information necessary to assign the RPA classes, i.e.
the best documented and validated score, was available.
Out of 99 patients in the database, 83 fulfilled this require-
ment and the other 16 were excluded. The score developed
by Rades et al. was evaluated in all 83 patients, BSBM in 82
patients, GPA in 74 patients, and SIR in 54 patients. The
patient characteristics and the percentage of missing values
for lesion number and volume are shown in Table 1. Per-
formance status prior to treatment was routinely docu-
mented in all patient charts. Information on certain
primary tumor features such as grading and HER2 receptor
status was available in less than 30% of the patients and
therefore not included in the analyses. Hormone receptor
status was known in 35 of 83 patients. Systemic treatment
(chemotherapy, hormonal therapy, trastuzumab) was pro-
vided as indicated for extracranial disease manifestations,
taking performance status, previous systemic therapy and
organ function into consideration. At the time of analysis,
3 patients were alive (follow-up 3, 9 and 24 months,
respectively). The Kaplan-Meier method was used to gener-
ate actuarial survival curves. These were compared with the
log rank test. Multivariate analysis of prognostic factors was
performed with the Cox proportional hazards model. A p-
value < 0.05 was considered statistically significant. The
analyses were performed with the SPSS statistical software.
Results
Table 2 briefly recapitulates the major features of the 5
scores. First we evaluated the RPA classification. The 3
RPA classes contained 8 (10%, class I), 43 (52%, class II)
and 32 (39%, class III) patients, respectively. Their
median survival times were 16.0, 6.0 and 3.0 months,
respectively (Figure 1). Thus, the prognostic value of the
RPA classes could be confirmed. The other score with 3
Table 1: Patient characteristics, n = 83 (no male patients included)
Median age, range 57 yrs., 29–76
% age <65 years vs. ≥ 65 years 81 vs. 19
Median KPS, range 70, 30–90
% KPS 80–90 vs. 70 vs. <70 37 vs. 23 vs. 40
Median time interval* 38 mo., 1–216
% single brain metastasis, multiple, unknown 37, 46, 17
Median number of brain metastases 2
Median volume of the largest lesion, unknown 15 ml, 24%
% without extracranial metastases 22
% with controlled primary tumor 96
% with complete/incomplete surgical resection of brain metastases before WBRT 7/1
% with radiosurgery before or concomitant to WBRT 6
% with salvage surgery or radiosurgery after WBRT 5
KPS: Karnofsky performance status, WBRT: whole brain radiotherapy, * from breast cancer diagnosis to brain metastasesBMC Cancer 2009, 9:105 http://www.biomedcentral.com/1471-2407/9/105
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prognostic classes is the SIR, which could be assigned in
54 cases. Here, the 3 classes contained 6 (11%), 37 (69%)
and 11 patients (20%), respectively. As shown in Figure 2,
the SIR also predicts the survival of this patient popula-
tion (median 18.8, 6.0 and 2.7 months, respectively). The
advantage of the SIR compared to RPA is that the tail of
long-term survivors in the most unfavourable prognostic
group is eliminated.
The 3 other scores contain 4 prognostic classes each.
When looking at the new graded prognostic assessment
(GPA) score, we discovered that only 5 of our patients
belonged to the 2 most favourable GPA classes. These
were therefore combined for the Kaplan-Meier analysis.
The large majority belonged to the low intermediate
group (n = 44, 59%) and the unfavourable group (n = 25,
34%). As shown in Figure 3, the difference between the 2
favourable classes and the low intermediate group is not
statistically significant. Median survival was 55, 6.8 and
2.7 months. In the BSBM system, the difference between
the 2 unfavourable classes is not statistically significant.
However, the most unfavourable class contains only 2
patients and the most favourable class only 7 (Figure 4).
For the score developed by Rades et al., the difference
between the 2 unfavourable classes is not statistically sig-
nificant either (Figure 5). Also here, only few patients
belonged to the most unfavourable (n = 7, 8%) and
favourable (n = 9, 11%) classes, respectively.
Regarding the prognostic factors in our patient popula-
tion, primary tumor control was not evaluated as almost
all patients had controlled primaries. Age, hormone
receptor status (note that information was available in
only 42% of patients) and diameter of the largest lesion in
the brain were not significant prognostic factors, while
KPS <70, presence of extracranial metastases, presence of
more than 1 brain metastasis and interval <38 months
were. The strongest impact was found for KPS, while the
others had similar hazard ratios in the multivariate model
(Table 3). With these 4 factors, which are not completely
identical to those from any of the known scores, a new
score was built. Taking the different hazard ratios into
account, we assigned 2 points for low KPS and 1 point
each for presence of extracranial metastases, presence of
more than 1 brain metastasis and interval <38 months.
Overall 68 patients had information on all parameters
available. Both a 3-tiered and a 4-tiered score were built
and each of them performed slightly better than the previ-
ously published 3- or 4-tiered scores (Figure 6 and 7).
Median survival for the groups in the 3-tiered score was
16.0, 5.5 and 2.7 months. For the 4-tiered score, 16.0, 5.5,
3.6 and 2.7 months were found. Another advantage of
this score is the improved balance in patient numbers. In
the 3-tiered score, the different prognostic classes contain
22, 38 and 40% of the patients (for the 4-tiered score: 19,
32, 18 and 31%). Finally, it was evaluated whether the
better performance of the new score could be explained by
the fact that 15 of 83 patients were excluded from the
analysis (because of missing information as explained
above). If the excluded patients would have been those
creating problems in the other systems, e.g., the tail of
long-term survivors in RPA class III, the new score would
not provide a real advantage. However, it was found that
the excluded patients belonged to class II (n = 11) or class
III with survival <11 months (n = 4).
Discussion
The present analysis attempts to shed more light on the
prediction of survival of patients with brain metastases
from breast cancer. Experienced clinicians will be able to
supplement the information provided by prognostic
scores such as RPA or GPA by factors that can not easily be
incorporated in such models. Examples include the
number of previously administered therapies, duration of
response, remaining systemic treatment options, bone
marrow function, weight loss etc. Despite all efforts to pre-
dict the outcome, some patients will likely respond to
treatment and do much better than predicted, while oth-
ers might die from unforeseeable events such as pulmo-
nary embolism, bowel perforation, severe infection etc. In
other words, even a very advanced and accurate prognos-
tic model remains a model, which provides less than per-
Table 2: The 5 prognostic scores
Score Performance status Age Extracranial 
metastases
Primary tumor 
control
Interval* Number of brain 
met.
Volume of brain 
met.
RPA
3 classes
included included included included
BSBM
4 classes
included included included
SIR
3 classes
included included included included included included
GPA
4 classes
included included included included
Rades et al.
4 classes
included included included included
* from breast cancer diagnosis to brain metastasesBMC Cancer 2009, 9:105 http://www.biomedcentral.com/1471-2407/9/105
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Actuarial survival curves according to the RPA score, p < 0.01 Figure 1
Actuarial survival curves according to the RPA score, p < 0.01.
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Actuarial survival curves according to the SIR score, p < 0.05 Figure 2
Actuarial survival curves according to the SIR score, p < 0.05.
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Actuarial survival curves according to the GPA score, p > 0.1 Figure 3
Actuarial survival curves according to the GPA score, p > 0.1.
0
25
50
75
100
0 3 6 9 12 15 18 21 24
3.0-4.0
1.5-2.5
0-1.0
Months from start of therapy
%
 
A
l
i
v
e
Actuarial survival curves according to the BSBM score, p > 0.1 Figure 4
Actuarial survival curves according to the BSBM score, p > 0.1.
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fect specificity and sensitivity. In an ideal world, the
authors' study group would have been larger and detailed
information on blood chemistry, haematology, HER2 sta-
tus etc. would have been available. Taken these caveats
into consideration, we can not conclude that we finally
arrived at the best possible prognostic model. Our present
analysis rather supports the hypothesis that a better
model than the ones derived from the general brain
metastases population can be developed for the patients
with primary breast cancer. Without doubt, the definitive
prognostic score can only be created from a very large
database.
The prognostic impact of the RPA score was previously
confirmed in a comparable patient population by Viani et
al. [9]. In their study, median survival was 11.7, 6.2 and
3.0 months in class I, II and III, respectively. Except for
class I (11.7 vs. 16.0 months), there is strong concordance
with the present data. Claude et al. and Le Scodan et al.
also reported a median survival of 3.0 months in RPA
class III [10,11]. No separate analyses were performed for
class I and II in these 2 studies. Interestingly, both studies
found that lymphopenia is an important and independ-
ent predictor of survival. Lymphopenia has not been
included in other analyses published so far and was not
Table 3: Overview of prognostic factors in the present group of patients
Parameter Univariate analysis (log rank test) Multivariate analysis 
(Cox regression analysis)
Included in final prognostic model
Primary tumor control not done
Age not significant (p = 0.09) not significant (p > 0.01)
Karnofsky performance status p < 0.05 p = 0.01, hazard ratio 3.6 yes
Extracranial metastases p < 0.05 p = 0.03, hazard ratio 2.1 yes
Interval from first cancer diagnosis 
to brain metastases
p < 0.05 p = 0.05, hazard ratio 1.8 yes
Number of brain metastases p < 0.05 p = 0.05, hazard ratio 2.0 yes
Diameter of the largest brain 
metastasis
not significant (p > 0.1) not included
Hormone receptor status not significant (p > 0.1) not included
Actuarial survival curves according to the score developed by Rades et al., p > 0.1 Figure 5
Actuarial survival curves according to the score developed by Rades et al., p > 0.1.
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Actuarial survival curves according to the breast cancer-specific score (3-tiered model), p < 0.01 Figure 6
Actuarial survival curves according to the breast cancer-specific score (3-tiered model), p < 0.01.
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Actuarial survival curves according to the breast cancer-specific score (4-tiered model), p < 0.05 Figure 7
Actuarial survival curves according to the breast cancer-specific score (4-tiered model), p < 0.05.
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available in our patients either. Mahmoud-Ahmed et al.
reported on patients treated with WBRT alone, i.e. a less
favourable group. Median survival was 8.1, 6.1 and 1.7
months in the three RPA classes (p = 0.01) [12]. The other
prognostic scores have not been evaluated in the previous
breast cancer studies. For the present cohort of patients
with brain metastases from breast cancer, the known 3-
tiered scores RPA and SIR were found to reflect the prog-
nosis, but not to a completely satisfactory degree. This
might be explained by the fact that these scores originally
were derived from mixed patient populations, where
those with breast cancer make up just a minority. Indeed
several recent analyses indicate that the prognostic factors
in patients with breast primaries are not identical to those
that define the known prognostic scores. Table 4 provides
an overview of these analyses. The present study also
arrives at prognostic factors, which are different from
those that make up the known scores. By using the 4 fac-
tors that we identified, a 3-tiered score can be created,
which performs slightly better than RPA and SIR and
which results in almost equally large patient groups.
In the recent literature a trend towards 4-tiered scores such
as GPA and BSBM can be found. As previously acknowl-
edged, the number of patients in the present study is not
high enough to fully evaluate the performance of these
scores in patients with breast cancer. Yet the important
question is what might be the clinical impact of expand-
ing from 3- to 4-tiered scores. Basically, the decision is
whether or not to provide any local treatment beyond
WBRT. Both surgery and radiosurgery were found to
improve survival in prognostically better patients with
brain metastases amenable to these procedures [13-15].
Given the survival curves derived from the present analy-
sis, the 2 better prognostic groups in the 3-tiered systems
in principle qualify for surgery or radiosurgery, while such
treatment might not be justified for many if not most of
the patients in the most unfavourable group. If one
doesn't want to withheld potentially useful treatment, the
group with the most unfavourable prognosis should be
kept small. Moving from Radiation Therapy Oncology
Group (RTOG)'s RPA to their new 4-tiered GPA score, the
size of the most unfavourable class can be reduced from
39 to 34%. Using the 3- vs. 4-tiered score developed from
the present database, a reduction from 40 to 31% can be
achieved. The survival difference between the 2 most
favourable prognostic groups in a 4-tiered system might
be statistically significant, but it is not very relevant for
decision making.
The challenge for the future is the validation of the current
findings in a much larger database, which ideally will con-
tain additional information on tumor biology and other
host factors (receptor status, lymphopenia etc. [16-25])
and thus allow for a head to head comparison of these fac-
tors with performance status, extracranial metastases (or
number of sites or disease status as suggested by different
studies listed in Table 4), number of brain metastases,
interval and age. The creation of such a database probably
will require collaboration between several institutions.
Conclusion
A variety of prognostic models describe the survival of
patients with brain metastases from breast cancer to a
more or less satisfactory degree. In the present group, the
best results were obtained with the RPA and SIR score,
Table 4: Prognostic impact (PI) of different tumor- and patient-related parameters
n PI of hormone receptor status PI of HER-2 status PI of various factors (multivariate)
Claude et al. [10] 120 none no data performance status, lymphopenia
Bartsch et al. [16] 174 none none performance status, number of metast. sites
Le Scodan et al. [11] 117 receptor negative sign. worse none performance status, lymphopenia, hormone 
receptor status
Nam et al. [17] 126 receptor negative sign. worse HER-2 negative sign. worse number of metast. sites, age, hormone and 
HER-2 receptor status, leptomeningeal disease
Eichler et al. [18] 83 none HER-2 negative sign. worse HER-2 receptor status, number of brain 
metast., local disease control
Melisko et al. [19] 112 receptor negative sign. worse none hormone receptor status, age, performance 
status, stable or responding systemic disease
Harputluoglu et al. [20] 144 none none number of brain metast.
Park et al. [21] 125 none HER-2 positive sign. worse HER-2 receptor status, performance status
Altundag et al. [23] 420 receptor negative sign. worse none age, hormone receptor status
Wronski et al. [25] 70 receptor negative sign. worse no data leptomeningeal disease, combined surgery and 
whole brain radiotherapy
Lee et al. [22] 198 no data no data performance status, number of brain metast.
Viani et al. [9] 174 no data no data extracranial metastases, RPA class
Mahmoud-Ahmed et al. [12] 116 no data no data performance status
Liu et al. [24] 48 no data no data performance status, number of brain met.BMC Cancer 2009, 9:105 http://www.biomedcentral.com/1471-2407/9/105
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respectively. However, the standard brain metastases
scores, which often were derived from mixed patient
groups (large percentage of lung cancer), might not fully
appreciate the unique biology and time course of this dis-
ease. It appears possible that inclusion of emerging prog-
nostic factors will improve the results and allow for
development and validation of a consensus score for
broad clinical application.
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